USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
American Biotechnology Co
Address:
7658 Standish Pl - Ste 107
Rockville, MD 20855
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
10
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $248,122.00 5
SBIR Phase II $495,000.00 1

Award List:

THE GOAL OF THIS PROJECT WILL BE TO SCREEN NEW DERIVATIVES OF L-ASCORBIC ACID ADDUCTS CLASSIFIED AS METHYLFURYLBUTYROLACTONES, ALSO REFERRED TO AS NAFOCARE B.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert w. veltri , PRINCIPAL INVESTIGATOR
Abstract:
The goal of this project will be to screen new derivatives of l-ascorbic acid adducts classified as methylfurylbutyrolactones, also referred to as nafocare b. working in collaboration with a synthetic organic chemistry group at west virginia university, we have determined that the parent compound,… More

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$49,593.00
Agency:
HHS
Principal Investigator:
Michael w. baseler , PRINCIPAL INVESTIGATOR
Abstract:
And its potential application to human hybridoma technology.this project involves determining the ability of a new class of synthetic biological response modifiers (brm) known as methylfurylbutyrolactones (mfbl) to augment the production of lymphokines (il-2, b-cell growth factor, and immune… More

ALTHOUGH INVESTIGATION INTO BIOLOGICAL RESPONSE MODIFIERS HAS INCREASED RECENTLY, MOST OF THE EFFORT HAS BEEN TOWARDS POTENTIATING THE HOST'S CELL-MEDIATED IMMUNITY.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$48,529.00
Agency:
HHS
Principal Investigator:
Peter e. maxim , PRINCIPAL INVESTIGATOR
Abstract:
Although investigation into biological response modifiers has increased recently, most of the effort has been towards potentiating the host's cell-mediated immunity. data accumulated by our laboratories indicate that the methylfurylbutyrolactone (mfbl) class of compounds represents new synthetic… More

INTERFACE

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert w veltri , PRINCIPAL INVESTIGATOR
Abstract:
A major objective of this study is to investigate the utility of a new and innovative liquid microcarrier (mc) system for cloning and propagating human tumor cells in vitro. this new patented technology is an oil emulsion of defined droplet size (100 to 200 mm) having a smooth, pliable, and… More

EVALUATION OF THE IMMUNE MODULATOR MFBL FOR ANTIVIRAL EFFICACY

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Dr Peter E Maxim
Abstract:
N/a

EVALUATION OF THE IMMUNE MODULATOR MFBL FOR ANTIVIRAL EFFICACY

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$495,000.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Dr Peter E Maxim
Abstract:
The methylfurylbutyrolactones (mfbl's) are a unique group of chemical compounds that comprise a new group of synthetic immunomodulators. the compounds are water soluble, relatively non-toxic, economical to produce in quantity, and effective when administered via the intravenous, intraperitoneal or… More